Tokyo, Japan and Cambridge, UK, 5 March 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals has achieved an additional early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX489, being developed by Centessa for the treatment of neuropsychiatric disorders. This milestone triggers a payment of US $3 million to Nxera pursuant to its research collaboration with Centessa. The milestone payment will be recognized as revenue in the…
Europa Biosite Acquires Stratech Scientific, Expanding Their Product Offering and Strengthening UK Customer Reach
Europa Biosite, a leading pan-European life science distribution group, today announced the acquisition of Stratech Scientific Limited by its UK subsidiary, Cambridge Bioscience. Stratech Scientific is a well-respected and long-established UK life science distributor, known for its high-quality research reagents and strong supplier partnerships.
This acquisition significantly expands Europa Biosite’s UK product offering and broadens its reach across academic and…
LONDON, UK and BRUSSELS, Belgium – March 5, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led a search for Evondos Group and is pleased to announce the placement of Tom Ellison as Chief Financial Officer (CFO). Evondos Group is the leading provider of automated medicine dispensing services in northern Europe. Their solutions ensure safe and timely medication for home care clients, improving patient safety, treatment outcomes and quality of life. By supporting healthcare professionals,…
Provides structured US market access for EvoLiver FDA-designated liver cancer surveillance test across health systems, payors and clinical stakeholders
Cambridge, UK, and Boston MA, USA, 04 March 2026: Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve chronic disease outcomes for at-risk patients, today announced it has been selected to join the Association of British HealthTech Industries (ABHI) US Accelerator. Building on the Company’s US presence, the programme will support the introduction of EvoLiver™, its FDA-designated liver cancer…
Drug development consultancy Boyds has appointed Kate Owen as Medical Director in its Clinical and Medical Affairs team.
With more than 25 years’ experience as a pharmaceutical physician specialising in early development oncology, haemato-oncology, clinical pharmacology and ATMPs, Kate began her career training as an anaesthetist before working for a CRO. She then spent 16 years at AstraZeneca where she worked as Medicine and Science Director. In 2016, Kate became an independent consultant working with companies around the globe across small molecules, biologics, medical devices and cell…
Prime.io - a london based cell line engineering service CRO company appoints Sir Tony Kouzarides to support long-term strategy for its Next Generation Cell Line Engineering Services.
Tony is a highly cited academic and entrepreneur who co-founded both the Milner Therapeutics Institute and Abcam (NASDAQ: ABCM). As scientific advisor, he will help guide prime.io's scientific strategy and explore new opportunities to raise awareness of the Company’s mission to edit genes and accelerate drug discovery.
Prime.io is a gene editing contract research organization (CRO) that uses AI-designed…
Cambridge, UK, 2nd March 2026: Babraham Research Campus Ltd (BRCL), which is responsible for the development and management of Babraham Research Campus, is delighted to announce the appointment of Dr Rich Ferrie to the role of Chief Executive Officer.
Rich joins Babraham Research Campus from LBIC (London Bioscience Innovation Centre Ltd), a subsidiary of the Royal Veterinary College and key provider of innovation space and support services for early and growth stage life science companies in London’s vibrant Knowledge Quarter. During his tenure as CEO, Rich led the expansion of LBIC…
Prime.io Ltd helps antibody and drug target validation teams to generate high-quality knock-in and knock-out cell models—fast. Powered by our proprietary AI designed CRISPR platform (commercial licence available), we deliver:
• 3x higher knock-in efficiency than conventional spCas9 in pool and single cancer/iPSC cell derived clone
• Up to 97% knock-out efficiency in single cancer/iPSC cell derived clone
• Reduced off-target activity and immunogenicity
• NGS-validated single-cell clones
• Single cell derived edited clone delivery in just 8–12 weeks (if cell doubling rate is around 24…
Building on strong efficacy results, the companies will expand their collaboration to 25,000 patients to identify safety, tolerability, and drug-specific response signals.OXFORD, UK and PORTLAND, ME – 25 February 2026 – Ovation.io, a leading human omics and clinical data company, and PrecisionLife, a precision medicine company transforming how complex chronic diseases are understood and managed, today announced the results of the first phase of their collaboration to develop drug-response biomarkers to quantitively predict the efficacy, safety and tolerability of glucagon-like…
Amsbio offers a comprehensive range of pre-made lentiviral particles for delivering target genes into most types of dividing and non-dividing mammalian cells in vitro and in vivo.
Lentiviral particles provide long-term, stable expression of genes, making them ideal for stable cell line engineering, CRISPR applications, and therapeutic gene transfer.
Key advantages of Amsbio lentiviral particles include their ease of use, high titer, purity, and safety features. These pre-made lentiviral particles come ready-to-use, eliminating the need for transfection reagents and saving…